Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment

ABSTRACT Background Long‐term childhood cancer survivors (CCS) may develop anthracycline‐induced cardiomyopathy. Our cross‐sectional study focused on the question of whether a central echocardiographic reference assessment is associated with a higher detection rate of cardiac dysfunction in a popula...

Full description

Saved in:
Bibliographic Details
Main Authors: Kristina Kleen, Judith Gebauer, Claudia Spix, Lea L. Kronziel, Inke König, Katja Baust, Gabriele Calaminus, Thorsten Simon, Barbara Hero, Oliver Zolk, Norbert Graf, Hashim Abdul‐Khaliq, Thorsten Langer
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.71158
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849221911534370816
author Kristina Kleen
Judith Gebauer
Claudia Spix
Lea L. Kronziel
Inke König
Katja Baust
Gabriele Calaminus
Thorsten Simon
Barbara Hero
Oliver Zolk
Norbert Graf
Hashim Abdul‐Khaliq
Thorsten Langer
author_facet Kristina Kleen
Judith Gebauer
Claudia Spix
Lea L. Kronziel
Inke König
Katja Baust
Gabriele Calaminus
Thorsten Simon
Barbara Hero
Oliver Zolk
Norbert Graf
Hashim Abdul‐Khaliq
Thorsten Langer
author_sort Kristina Kleen
collection DOAJ
description ABSTRACT Background Long‐term childhood cancer survivors (CCS) may develop anthracycline‐induced cardiomyopathy. Our cross‐sectional study focused on the question of whether a central echocardiographic reference assessment is associated with a higher detection rate of cardiac dysfunction in a population‐based cohort of affected children with neuroblastoma or nephroblastoma. We also examined the prevalence of anthracycline‐induced cardiomyopathy and its risk factors. Methods and Patients The cohort of this subproject comprises 370 nephroblastoma or neuroblastoma survivors diagnosed with cancer between 1990 and 2012. At study entry, participants were younger than 18 years old, had been treated with anthracyclines, and had no documented previous cardiac disease. Data were collected via patient questionnaires, cardiologic examinations in the network of adults with congenital heart defects (Erwachsene mit angeborenem Herzfehler [EMAH]) and a reference assessment of the recorded echocardiography. Results The prevalence of cardiomyopathy in the study cohort (mean age: 12 years) was 6.3% at a median of 9.1 years after initial cancer diagnosis. Risk factors were an age under 5 years at tumor diagnosis and concomitant treatment with cyclophosphamide or radiation. As a central and novel finding, the detection rates by the EMAH cardiologists and the reference center are similarly high but discrepant. Discussion Limitations were mainly due to the low responder rate and incomplete data. This study established a nationwide competence network linking pediatric oncology and cardiology centers across six university hospitals in Germany, enabling data collection on pediatric CCS. Despite lower case numbers compared to adult CCS cohorts, meaningful data were gathered and analyzed. Conclusion Cardiac late effects after anthracycline‐based therapy in childhood affect a relevant proportion of long‐term CCS at pediatric age. In order to enable timely diagnosis and treatment, preventive examinations are essential and might benefit from additional central reference assessments. Discrepancy in detection of cardiomyopathy by reference and EMAH cardiologists requires further investigation.
format Article
id doaj-art-e5571292d2784186a9484ea79f8b7e44
institution Kabale University
issn 2045-7634
language English
publishDate 2025-08-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-e5571292d2784186a9484ea79f8b7e442025-08-26T10:58:44ZengWileyCancer Medicine2045-76342025-08-011416n/an/a10.1002/cam4.71158Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference AssessmentKristina Kleen0Judith Gebauer1Claudia Spix2Lea L. Kronziel3Inke König4Katja Baust5Gabriele Calaminus6Thorsten Simon7Barbara Hero8Oliver Zolk9Norbert Graf10Hashim Abdul‐Khaliq11Thorsten Langer12Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine University Hospital Schleswig‐Holstein Lübeck GermanyMedical Clinic 1 University Hospital Schleswig‐Holstein Lübeck GermanyGerman Childhood Cancer Registry Mainz GermanyInstitute of Biometry and Statistics, University of Lübeck Lübeck GermanyInstitute of Biometry and Statistics, University of Lübeck Lübeck GermanyPaediatric Haematology and Oncology University Hospital Bonn Bonn GermanyPaediatric Haematology and Oncology University Hospital Bonn Bonn GermanyPaediatric Oncology and Haematology University Hospital Cologne Cologne GermanyPaediatric Oncology and Haematology University Hospital Cologne Cologne GermanyInstitute for Clinical Pharmacology Immanuel Clinic Rüdersdorf, Brandenburg Medical School Rüdersdorf GermanyPaediatric Haematology and Oncology University Hospital Homburg/Saar Homburg GermanyPaediatric Cardiology University Hospital Homburg/Saar Homburg GermanyPaediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine University Hospital Schleswig‐Holstein Lübeck GermanyABSTRACT Background Long‐term childhood cancer survivors (CCS) may develop anthracycline‐induced cardiomyopathy. Our cross‐sectional study focused on the question of whether a central echocardiographic reference assessment is associated with a higher detection rate of cardiac dysfunction in a population‐based cohort of affected children with neuroblastoma or nephroblastoma. We also examined the prevalence of anthracycline‐induced cardiomyopathy and its risk factors. Methods and Patients The cohort of this subproject comprises 370 nephroblastoma or neuroblastoma survivors diagnosed with cancer between 1990 and 2012. At study entry, participants were younger than 18 years old, had been treated with anthracyclines, and had no documented previous cardiac disease. Data were collected via patient questionnaires, cardiologic examinations in the network of adults with congenital heart defects (Erwachsene mit angeborenem Herzfehler [EMAH]) and a reference assessment of the recorded echocardiography. Results The prevalence of cardiomyopathy in the study cohort (mean age: 12 years) was 6.3% at a median of 9.1 years after initial cancer diagnosis. Risk factors were an age under 5 years at tumor diagnosis and concomitant treatment with cyclophosphamide or radiation. As a central and novel finding, the detection rates by the EMAH cardiologists and the reference center are similarly high but discrepant. Discussion Limitations were mainly due to the low responder rate and incomplete data. This study established a nationwide competence network linking pediatric oncology and cardiology centers across six university hospitals in Germany, enabling data collection on pediatric CCS. Despite lower case numbers compared to adult CCS cohorts, meaningful data were gathered and analyzed. Conclusion Cardiac late effects after anthracycline‐based therapy in childhood affect a relevant proportion of long‐term CCS at pediatric age. In order to enable timely diagnosis and treatment, preventive examinations are essential and might benefit from additional central reference assessments. Discrepancy in detection of cardiomyopathy by reference and EMAH cardiologists requires further investigation.https://doi.org/10.1002/cam4.71158
spellingShingle Kristina Kleen
Judith Gebauer
Claudia Spix
Lea L. Kronziel
Inke König
Katja Baust
Gabriele Calaminus
Thorsten Simon
Barbara Hero
Oliver Zolk
Norbert Graf
Hashim Abdul‐Khaliq
Thorsten Langer
Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
Cancer Medicine
title Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
title_full Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
title_fullStr Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
title_full_unstemmed Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
title_short Anthracycline‐Induced Cardiomyopathy After Nephro‐/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment
title_sort anthracycline induced cardiomyopathy after nephro neuroblastoma in childhood the importance of cardiological reference assessment
url https://doi.org/10.1002/cam4.71158
work_keys_str_mv AT kristinakleen anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT judithgebauer anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT claudiaspix anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT lealkronziel anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT inkekonig anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT katjabaust anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT gabrielecalaminus anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT thorstensimon anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT barbarahero anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT oliverzolk anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT norbertgraf anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT hashimabdulkhaliq anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment
AT thorstenlanger anthracyclineinducedcardiomyopathyafternephroneuroblastomainchildhoodtheimportanceofcardiologicalreferenceassessment